nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2026, 18, v.41 2983-2987
子宫动脉血流参数联合血清糖类抗原125甲胎蛋白对子痫前期患者不良妊娠结局的预测价值
基金项目(Foundation): 浙江省中医药科技计划项目(2022ZX012)
邮箱(Email):
DOI: 10.19829/j.zgfybj.issn.1001-4411.2026.18.002
发布时间: 2026-09-08
出版时间: 2026-09-08
移动端阅读
摘要:

目的 探讨子宫动脉(UtA)血流参数联合血清糖类抗原125(CA125)、甲胎蛋白(AFP)对子痫前期(PE)患者不良妊娠结局的预测价值。方法 选取2022年1月—2024年12月浙江大学医学院附属邵逸夫医院龙游分院收治的50例PE患者为研究对象(PE组),另选择同期产检的40例健康孕妇作为对照(NC组);酶联免疫吸附测定(ELISA)检测血清CA125、 AFP水平;测定Ut A血流参数;评价PE患者的病情程度,分为重度PE(Ⅱ组,n=17)和轻度PE(Ⅰ组,n=33);随访PE患者的妊娠结局,分为不良妊娠结局(不良组,n=13)和妊娠结局良好(良好组,n=37);采用比值比分析PE患者妊娠结局的影响因素;受试者工作特征曲线(ROC)分析CA125、 AFP、 PI、 RI及S/D对妊娠结局的预测价值。结果 PE组较NC组PI、 RI、 S/D及血清CA125、 AFP水平均升高(P<0.05); Ⅱ组较Ⅰ组PI、 RI、 S/D及血清CA125、 AFP水平均升高(P<0.05);不良组较良好组PI、 RI、 S/D及血清CA125、 AFP水平均升高(P<0.05); CA125高水平、 AFP高水平、 PI高水平、 RI高水平、 S/D高水平患者发生不良妊娠结局的风险分别是CA125低水平、 AFP低水平、 PI低水平、 RI低水平及S/D低水平患者的3.333倍(95%CI:1.040~10.687)、 3.333倍(95%CI:1.040~10.687)、 5.500倍(95%CI:1.355~22.325)、 3.611倍(95%CI:1.127~11.575)、 12.000倍(95%CI:1.685~85.470); CA125、 AFP、 PI、 RI、 S/D单独及联合预测不良妊娠结局的曲线下面积(AUC)分别为0.834、 0.712、 0.711、 0.861、 0.650、 0.969,联合预测价值显著高于单独预测(Z=2.424、 2.615、2.839、 2.236、 3.374,均P<0.05)。结论 PE患者血清Ut A血流参数PI、 RI、 S/D及血清AFP、 CA125水平均升高,联合检测对患者妊娠结局有良好的预测价值。

Abstract:

Objective To explore the predictive value of uterine artery(UtA) flow parameters combined with serum carbohydrate antigen 125(CA125) and alpha-fetoprotein(AFP) for adverse pregnancy outcomes in patients with preeclampsia(PE).Methods Totally 50 patients with PE who were admitted to our hospital from January 2022 to December 2024 were included in the study(PE group), and 40 healthy pregnant women who underwent prenatal check ups in our hospital during the same period were selected as the control group(NC group). Enzyme-linked immunosorbent assay(ELISA) was used to detect the levels of serum CA125 and AFP. Ut A blood flow parameters were measured. The severity of PE patients was evaluated, and they were assigned into severe PE(group Ⅱ, n= 17) and mild PE(group I, n= 33). The pregnancy outcomes of the follow-up patients with PE were classified as adverse pregnancy outcomes(adverse group, n= 13) and good pregnancy outcomes(good group, n= 37). The odds ratio analysis was used to investigate the influencing factors of pregnancy outcomes in patients with PE; receiver operating characteristic curve(ROC) analysis was conducted to evaluate the predictive value of CA125, AFP, PI, RI, and S/D for pregnancy outcomes.Results The PI, RI, S/D values, as well as the levels of serum CA125 and AFP in the PE group were higher than those in the NC group(P<0. 05). The PI, RI, S/D, as well as levels of serum CA125 and AFP in group Ⅱ were higher than those in group I(P<0. 05). The PI, RI, S/D, as well as levels of serum CA125 and AFP in the adverse group were all higher than those in the good group(P<0. 05). The risk of adverse pregnancy outcomes for patients with high levels of CA125, AFP, PI, RI, and S/D was 3. 333 times(95%CI: 1. 040-10. 687), 3. 333 times(95%CI: 1. 040-10. 687), 5. 500 times(95%CI: 1. 355-22. 325), 3. 611 times(95%CI: 1. 127-11. 575), 12. 000 times(95%CI: 1. 685-85. 470) that of patients with low levels of CA125, AFP, PI, RI, and S/D, respectively. The area under the curve(AUC) values for CA125, AFP, PI, RI, S/D alone and in combination for predicting adverse pregnancy outcomes were 0. 834, 0. 712, 0. 711, 0. 861, 0. 650, and 0. 969, respectively. The combined prediction value was obviously higher than that of the individual predictions(Z= 2. 424, 2. 615, 2. 839, 2. 236, 3. 374, all P<0. 05).Conclusion The serum UtA flowparameters(PI,RI,SD)andthelevelsofserum AFP and CA125 in patients with PE are elevated. Inaddition,the combined detection has a good predictive value for the pregnancy outcome of the patients.

参考文献

[1]Kusuma GD, Georgiou HM, Perkins AV, et al. Mesenchymal stem/stromal cells and their role in oxidative stress associated with preeclampsia[J]. Yale J Biol Med, 2022, 95(1):115-127.

[2]Cui J, Yang Z, Ma R, et al. Placenta-targeted treatment strategies for preeclampsia and fetal growth restriction:an opportunity and major challenge[J]. Stem Cell Rev Rep, 2024, 20(6):1501-1511.

[3]赵文杰,王晓华,侯东霞.子痫前期影响因素及预测模型的研究进展[J].现代妇产科进展, 2025, 34(7):553-556.

[4]姚伟红,吴艳红,何楠楠.血管阻力、子宫动脉血流参数、胎盘生长因子对早期妊娠期高血压并发先兆子痫的预测价值[J].中国实用医刊, 2025, 52(6):26-29.

[5]罗福梅,雷阿明,史艳飞,等.子宫动脉血流动力学联合血清PLGF、 CA125对子痫前期的预测价值[J].河北医药, 2025,47(4):551-554, 559.

[6]谷金丽,马勤宜,孙晓琴.血清AFP、 β-HCG、 uE3联合缩宫素使用剂量对妊娠合并肥胖初产妇不良妊娠结局的预测价值[J].分子诊断与治疗杂志, 2025, 17(10):2031-2033, 2037.

[7]中华医学会妇产科学分会妊娠期高血压疾病学组.妊娠期高血压疾病诊治指南(2020)[J].中华妇产科杂志, 2020, 55(4):227-238.

[8]Zhaoer Y, Mingming G, Wei Z, et al. Extracellular vesicles for the treatment of preeclampsia[J]. Tissue Cell, 2022, 77(1):101860.

[9]刘娇兰,刘琼,李仲均,等.胎盘生长因子、血小板参数及子宫动脉血流参数预测子痫前期的临床意义[J].临床医学研究与实践, 2022, 7(4):41-44.

[10]冯倩.子宫动脉超声多普勒血流参数诊断早发型子痫前期的价值[J].中国实用医刊, 2025, 52(18):91-94.

[11]Zhang M, Cheng S, Jin Y, et al. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2):188503.

[12]Bhatia P, Goel P, Mehra R, et al. Correlation of serum cancer antigen-125(CA-125)levels with severity of pre-eclampsia[J]. J Obstet Gynaecol India, 2023, 73(1):240-246.

[13]Balint O, Secosan C, Pirtea L. Role of CA-125 level as a marker in the management of severe pre-eclampsia[J]. Healthcare(Basel), 2022, 10(12):2474.

[14]Cao Y, Li W, Ma L. Assessment of the prognostic value of CA125for miscarriage risk in patients with threatened abortion:a systematic review and meta-analysis[J]. PLoS One, 2025, 20(6):0326384.

[15]Yeo YH, Lee YT, Tseng HR, et al. Alpha-fetoprotein:Past, present, and future[J]. Hepatol Commun, 2024, 8(5):422.

[16]Dai X, Zhang H, Wu B, et al. Correlation between elevated maternal serum alpha-fetoprotein and ischemic placental disease:a retrospective cohort study[J]. Clin Exp Hypertens, 2023, 45(1):2175848.

[17]Sovio U, Gaccioli F, Cook E, et al. Association between adverse pregnancy outcome and placental biomarkers in the first trimester:a prospective cohort study[J]. BJOG, 2024, 131(6):823-831.

[18]Aviram A, Mei-Dan E, Cassir G, et al. Technical Update No. 462:Abnormal maternal serum markers and adverse pregnancy outcomes[J]. J Obstet Gynaecol Can, 2025, 47(9):103060.

[19]郑秋咪,徐小兰,何燕莲,等.血清连接蛋白-4联合子宫动脉血流参数预测子痫前期患者不良妊娠结局的价值[J].中国性科学, 2025, 34(2):61-65.

[20]袁翱龙,崔利娜,徐静,等.血清中期因子、维生素E结合蛋白与早发型重度子痫前期患者胎儿生长受限的关系研究[J].海南医学, 2026, 37(1):45-50.

基本信息:

DOI:10.19829/j.zgfybj.issn.1001-4411.2026.18.002

中图分类号:R714.244

引用信息:

[1]徐春丽,沈晨,叶寨芳.子宫动脉血流参数联合血清糖类抗原125甲胎蛋白对子痫前期患者不良妊娠结局的预测价值[J].中国妇幼保健,2026,41(18):2983-2987.DOI:10.19829/j.zgfybj.issn.1001-4411.2026.18.002.

基金信息:

浙江省中医药科技计划项目(2022ZX012)

发布时间:

2026-09-08

出版时间:

2026-09-08

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文